Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers
Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate?
Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers
Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate?